News
Patients with prior treatment for diabetic macular edema (DME) may require more frequent dosing of aflibercept (Eylea), according to a subgroup analysis of the PHOTON trial presented at the recent ...
EyePoint Pharmaceuticals' Duravyu shows promising Phase 2 results in DME, with potential for less frequent dosing. Check out ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback